Israeli Researchers Begin World’s First Clinical Trial Of RNA Therapy For Pancreatic Cancer.

Israeli Researchers Begin World’s First Clinical Trial of RNA Therapy for Pancreatic Cancer. Israeli researchers have launched the world’s first clinical trial of an experimental RNA-based therapy designed to target KRAS mutations in patients with pancreatic cancer.The groundbreaking study aims to evaluate the safety and effectiveness of the novel treatment, which is specifically developed to attack KRAS gene mutations—one of the most common genetic drivers of pancreatic cancer.Researchers said the experimental RNA therapy represents a promising advancement in the search for more precise and effective treatments for one of the deadliest forms of cancer.

If successful, the trial could pave the way for a new generation of targeted cancer therapies, offering renewed hope for patients with pancreatic cancer linked to KRAS mutations.The clinical trial marks a significant milestone in cancer research and underscores ongoing efforts to develop innovative RNA-based treatments for difficult-to-treat cancers.